2. Epigenetics Anti-infection
  3. METTL3 HIV
  4. CHMA1004

CHMA1004  (Synonyms: Methyl piperazine-2-carboxylate; METTL3 activator-1 free base)

Cat. No.: HY-W125425
Handling Instructions Technical Support

CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1 free base) is a METTL3/METTL14/WTAP methyltransferase complex activator. CHMA1004 exhibits neuroprotective and anxiolytic potential by enhancing m6A methylation modification of RNA. CHMA1004 promotes HIV replication in an infection context. CHMA1004 can be used in studies related to anxiety disorders and HIV-1 infection.

For research use only. We do not sell to patients.

CHMA1004

CHMA1004 Chemical Structure

CAS No. : 2758-98-7

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of CHMA1004:

Other Forms of CHMA1004:

CHMA1004 Related Antibodies

Top Publications Citing Use of Products

View All HIV Isoform Specific Products:

View All Isoforms
HIV HIV-1 HIV-2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1 free base) is a METTL3/METTL14/WTAP methyltransferase complex activator. CHMA1004 exhibits neuroprotective and anxiolytic potential by enhancing m6A methylation modification of RNA. CHMA1004 promotes HIV replication in an infection context. CHMA1004 can be used in studies related to anxiety disorders and HIV-1 infection[1][2].

In Vitro

CHMA1004 protects human stem cell-derived dopamine neurons against 6-OHDA-induced cell death[1].
CHMA1004 (Compound 4) (0.001-10 μM; 48 h) induces a concentration-dependent increase in HIV-1 p24 release from ACH-2 cells[2].
CHMA1004 (10 μM; 48 h) promotes the production of infectious HIV-1 viral particles in ACH-2 cells, which is verified by enhanced luciferase activity in infected TZM-bl cells[2].
CHMA1004 (10 μM; 48 h) increases the m6A methylation level in mRNA of ACH-2 cells to more than twice the original level, and elevates the m6A methylation level in HIV-1 viral RNA by approximately 18%[2].
CHMA1004 (1 nM-10 μM) slightly increases the m6A methylation level in mRNA of HEK-293 cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CHMA1004 Related Antibodies

ELISA Assay[2]

Cell Line: ACH-2 cells (harboring HIV-1 provirus)
Concentration: 0.001 μM, 0.01 μM, 0.1 μM, 1 μM, 10 μM
Incubation Time: 48 h
Result: Caused a concentration-dependent increase in HIV-1 p24 release (measured as optical density at 450 nm).
Showed statistically significant increases at 0.1 μM, 1 μM, and 10 μM compared to control.
In Vivo

CHMA1004 (1-5 mg/kg; i.p.; daily, 17-18 days; or single dose) elicits anxiolytic-like and locomotor activating effects in male and female Wistar rats, alters brain monoamine levels and striatal gene expression linked to neuropsychiatric pathways, and lacks strong psychostimulant properties[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar rats (male and female; 3 months old at study start; male body weight 499 g, female body weight 290 g)[1]
Dosage: 1 mg/kg (subchronic; acute microdialysis); 5 mg/kg (subchronic; acute microdialysis)
Administration: i.p.; daily; 17-18 days (subchronic); i.p.; single dose (acute microdialysis)
Result: Increased time spent moving, line crossings, and rearings in female rats in acute open field test.
Showed a similar non-significant tendency in males at 5 mg/kg in acute open field test.
Reduced faecal boli counts in male rats at 5 mg/kg in acute open field test.
Increased head-dips in female rats during the first repeated elevated zero-maze test at 1 mg/kg and 5 mg/kg.
Increased open quadrant entries in male rats during the second repeated elevated zero-maze test at 5 mg/kg.
Reduced stretched-attend postures in male rats during the first repeated elevated zero-maze test at 5 mg/kg.
Increased swimming time and reduced struggling time in female rats on both test days of repeated forced swimming test at 1 mg/kg and 5 mg/kg.
Tended to increase locomotion in male rats during amphetamine challenge at subchronic 5 mg/kg.
Reduced the baseline sex difference in 50-kHz USVs by increasing vocalisations in males and reducing them in females during amphetamine challenge at subchronic 5 mg/kg.
Had no significant effect on extracellular striatal dopamine levels in acute microdialysis at 1 mg/kg and 5 mg/kg.
Increased normetanephrine (NMN) levels in males and females in striatum at subchronic 5 mg/kg.
Increased the DOPAC/DA ratio in males in striatum at subchronic 5 mg/kg.
Decreased the DOPAC/DA ratio in females in striatum at subchronic 1 mg/kg.
Increased NMN levels in males in frontal cortex at subchronic 1 mg/kg and 5 mg/kg.
Increased noradrenaline (NA) levels in males in frontal cortex at subchronic 5 mg/kg.
Increased homovanillic acid (HVA) levels in males in locus coeruleus at subchronic 1 mg/kg.
Decreased HVA levels in females in locus coeruleus at subchronic 1 mg/kg and 5 mg/kg.
Increased NA levels in males and females in ventral tegmental area at subchronic 1 mg/kg.
Altered expression of 172 genes (e.g., downregulated Acsm5, Gpr83; upregulated Fgr, Hes1) in striatum of females at subchronic 1 mg/kg.
Altered expression of 120 genes (e.g., downregulated Vwa5b2, Peli1; upregulated Nbl1, Mdga1) in striatum of females at subchronic 5 mg/kg.
Showed consistent expression changes across doses in seven overlapping genes (Galns, Hps3, Misp3, Nbl1, Samd4a, Slc28a2, Spon2) in striatum of females.
Molecular Weight

144.17

Formula

C6H12N2O2
CAS No.
SMILES

COC(=O)C1CNCCN1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CHMA1004 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CHMA10042758-98-7Methyl piperazine-2-carboxylateMETTL3 activator-1CHMA 1004CHMA-1004METTL3HIVMethyltransferase-like 3Human immunodeficiency virusratsHIV-1 infectionhuman dopamine neuronsanxietydopamine neuron viabilityMETTL3/METTL14 complexTZM-bl cellsACH-2 cellsHEK-293 cellsRNA m6A methylationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CHMA1004
Cat. No.:
HY-W125425
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.